These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11385497)

  • 21. Microbiology. Translocation of anthrax toxin: lord of the rings.
    von Heijne G
    Science; 2005 Jul; 309(5735):709-10. PubMed ID: 16051774
    [No Abstract]   [Full Text] [Related]  

  • 22. Where and how do anthrax toxins exit endosomes to intoxicate host cells?
    Puhar A; Montecucco C
    Trends Microbiol; 2007 Nov; 15(11):477-82. PubMed ID: 17983750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
    Sloat BR; Shaker DS; Le UM; Cui Z
    FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raftlike polyvalent inhibitors of the anthrax toxin: modulating inhibitory potency by formation of lipid microdomains.
    Rai PR; Saraph A; Ashton R; Poon V; Mogridge J; Kane RS
    Angew Chem Int Ed Engl; 2007; 46(13):2207-9. PubMed ID: 17310484
    [No Abstract]   [Full Text] [Related]  

  • 25. Microbiology. A binding contract for anthrax.
    Bull JJ; Parrish CR
    Science; 2002 Jul; 297(5579):201-2. PubMed ID: 12114612
    [No Abstract]   [Full Text] [Related]  

  • 26. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
    Xiong Y; Wiltsie J; Woods A; Guo J; Pivnichny JV; Tang W; Bansal A; Cummings RT; Cunningham BR; Friedlander AM; Douglas CM; Salowe SP; Zaller DM; Scolnick EM; Schmatz DM; Bartizal K; Hermes JD; MacCoss M; Chapman KT
    Bioorg Med Chem Lett; 2006 Feb; 16(4):964-8. PubMed ID: 16338135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiation of an anthrax DNA vaccine with electroporation.
    Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
    Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of anthrax lethal factor based upon N-oleoyldopamine.
    Gaddis BD; Rubert Pérez CM; Chmielewski J
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2467-70. PubMed ID: 18314330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
    Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
    Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthrax toxin: the long and winding road that leads to the kill.
    Abrami L; Reig N; van der Goot FG
    Trends Microbiol; 2005 Feb; 13(2):72-8. PubMed ID: 15680766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the development of next-generation anthrax vaccines.
    Friedlander AM; Little SF
    Vaccine; 2009 Nov; 27 Suppl 4():D28-32. PubMed ID: 19837282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody.
    Kasuya K; Boyer JL; Tan Y; Alipui DO; Hackett NR; Crystal RG
    Mol Ther; 2005 Feb; 11(2):237-44. PubMed ID: 15668135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRP6 holds the key to the entry of anthrax toxin.
    Bann JG; Cegelski L; Hultgren SJ
    Cell; 2006 Mar; 124(6):1119-21. PubMed ID: 16564002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
    Gupta M; Alam S; Bhatnagar R
    Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anthrax protective antigen (PA63) bound conformation of a peptide inhibitor of the binding of lethal factor to PA63: as determined by trNOESY NMR and molecular modeling.
    Hicks RP; Bhattacharjee AK; Koser BW; Traficante DD
    J Med Chem; 2004 Oct; 47(22):5347-55. PubMed ID: 15481973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Manipulation of host signalling pathways by anthrax toxins.
    Turk BE
    Biochem J; 2007 Mar; 402(3):405-17. PubMed ID: 17313374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioterrorism watch. Anthrax aftermath: adverse drug reactions, vaccine controversy undercut CDC extended treatment offer.
    Evans G
    Hosp Peer Rev; 2002 Mar; 27(3):suppl 1-4. PubMed ID: 11905387
    [No Abstract]   [Full Text] [Related]  

  • 38. Anthrax. 'Borrowed immunity' may save future victims.
    Enserink M
    Science; 2002 Feb; 295(5556):777. PubMed ID: 11823609
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel pharmacophore model for the design of anthrax lethal factor inhibitors.
    Yuan H; Johnson SL; Chen LH; Wei J; Pellecchia M
    Chem Biol Drug Des; 2010 Sep; 76(3):263-8. PubMed ID: 20572812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three steps to targeting anthrax toxin.
    Lindsay J
    Trends Mol Med; 2002 Jan; 8(1):6. PubMed ID: 11796256
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.